---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-074450"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2023-06-26T23:59:59+00:00"
generated_at: "2026-06-13T17:06:25.868261+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# NextCure adopts amended bylaws, elects three directors, ratifies auditor at 2023 annual meeting

## Summary
- Bylaws amended June 22, 2023 to incorporate Delaware law updates and universal proxy rule requirements.
- Stockholders elected Class I directors Anne Borgman, John G. Houston, and Garry A. Nicholson.
- Ratified Ernst & Young as independent auditor for fiscal year ending Dec 31, 2023 (19.67M for, 155k against).

## SEC filing metadata
- accession: 0001104659-23-074450
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2023-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000110465923074450/0001104659-23-074450-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000110465923074450/tm2319533d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-074450
- JSON: https://secwatch.observer/filing/0001104659-23-074450.json
- Plain text: https://secwatch.observer/filing/0001104659-23-074450.txt

## Key facts
- Governance Changes
  NextCure, Inc.: Amended and restated bylaws to update adjournment procedures, stockholder meeting lists, director nomination rules, and universal proxy rules compliance (effective 2023-06-22).
  - Change: bylaw amendment
  - Effective: 2023-06-22
  source text: On June 22, 2023, the board of directors (the “Board”) of NextCure, Inc. (the “Company”) approved and adopted the Second Amended and Restated Bylaws of the Company (the “A&R Bylaws”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661059/000110465923074450/0001104659-23-074450-index.htm
- Shareholder Votes
  NextCure, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2023 at the 2023-06-22 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: On June 22, 2023, the Company held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders: (i) elected the three Class I members of the Board, each to serve for a three-year term expiring at the Company’s 2026 Annual Meeting of Stockholders and until such director’s earlier death, resignation, or removal from the Board; and (ii) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661059/000110465923074450/0001104659-23-074450-index.htm
- Shareholder Votes
  NextCure, Inc. shareholders approved Election of Class I Directors at the 2023-06-22 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-22
  source text: On June 22, 2023, the Company held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders: (i) elected the three Class I members of the Board, each to serve for a three-year term expiring at the Company’s 2026 Annual Meeting of Stockholders and until such director’s earlier death, resignation, or removal from the Board; and (ii) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661059/000110465923074450/0001104659-23-074450-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.